AngioDynamics, Inc. has announced a significant advancement in cancer treatment accessibility as Medicare will cover irreversible electroporation (IRE) for prostate and liver cancers starting July 5, 2026. This coverage, established by Palmetto GBA under Local Coverage Determination (LCD L40205), follows the activation of Category I CPT codes by the American Medical Association, which recognizes the clinical effectiveness of IRE procedures. The coverage is specifically for patients with favorable intermediate-risk prostate cancer and those with metastatic colorectal cancer to the liver who cannot undergo traditional surgical options. IRE utilizes high-voltage electrical pulses to ablate cancer cells while preserving critical surrounding structures, thus addressing significant quality-of-life concerns for patients. AngioDynamics' Senior Vice President, Juan Carlos Serna, emphasized the importance of this development in enhancing patient access to effective treatment options. The company is poised to support physicians in leveraging this technology as it seeks to expand its reach across additional payer jurisdictions.